In the past 24 months, Amgen completed its largest acquisition to date by purchasing Horizon Therapeutics for approximately $27.8 billion in October 2023, significantly expanding its portfolio in rare disease treatments, particularly for conditions like thyroid eye disease. This move was aimed at bolstering Amgen's growth amid patent expirations on some of its key drugs. Additionally, in 2024, Amgen reported strong financial results with a focus on its obesity drug candidate MariTide, which showed promising Phase 2 results and positioned the company in the competitive weight-loss market. The company also faced regulatory scrutiny but advanced its biosimilar programs, including the launch of new biosimilars for cancer treatments in various markets. These developments highlight Amgen's strategic push towards innovation and diversification in a rapidly evolving biotech landscape.

Amgen Inc. is a leading biotechnology company headquartered in Thousand Oaks, California, with a global presence and a workforce of over 26,000 employees focused on discovering, developing, and delivering innovative human therapeutics. Founded in 1980, it has grown into one of the world's largest independent biotech firms, specializing in areas like oncology, inflammation, bone health, and cardiovascular disease. Currently, Amgen is positioned as a pioneer in biologics, leveraging advanced manufacturing and research capabilities to address unmet medical needs. Its product lineup includes blockbuster drugs such as Enbrel for rheumatoid arthritis and Prolia for osteoporosis, generating billions in annual revenue. For young professionals in software engineering, sales, or product roles, Amgen offers opportunities to contribute to cutting-edge healthcare solutions in a stable, innovative environment.

Amgen's tech department excels in integrating artificial intelligence and machine learning into drug discovery processes, providing a competitive edge through platforms like the Amgen Data Lake, which analyzes vast datasets for faster therapeutic development. The company employs advanced software for bioinformatics, predictive modeling, and digital health tools, including apps for patient monitoring and clinical trial management. In the biotech industry, which is highly positioned for innovation due to rapid advancements in genomics and personalized medicine, Amgen stands out with its investments in digital transformation. Its reputation for career development is strong, offering mentorship programs and rotational opportunities, while salaries for tech roles average around $120,000-$150,000 annually, competitive within the sector according to industry salary data. Young professionals can expect a collaborative culture that values tech-driven innovation in healthcare.

Amgen faces challenges from patent cliffs on major drugs like Neulasta, leading to revenue pressures from biosimilar competition, and increasing regulatory hurdles in drug approvals that can delay launches. Opportunities lie in expanding its pipeline in oncology and rare diseases, capitalizing on the Horizon acquisition to tap into high-growth markets. Threats include intense competition from rivals like Pfizer and Eli Lilly, who are advancing in similar therapeutic areas, as well as potential impacts from healthcare policy changes affecting pricing. The company's heavy reliance on a few blockbuster products poses risks if new innovations falter. Overall, Amgen must navigate these dynamics to sustain its market leadership in biotechnology.